Enfortumab Vedotin/Pembrolizumab: New Hope for Muscle-Invasive Bladder Cancer

For patients facing muscle-invasive bladder cancer (MIBC) who aren’t candidates for standard cisplatin-based chemotherapy, a new treatment approach combining enfortumab vedotin and pembrolizumab is showing remarkable promise. Recent data suggest this combination, administered before and after surgery, significantly improves outcomes compared to surgery alone, marking the first chemotherapy-free regimen to demonstrate superiority in this setting. This could represent a substantial shift in how MIBC is treated, offering a vital option for a population often facing limited choices.

A New Option for Cisplatin-Ineligible Patients

Cisplatin-based chemotherapy has long been the cornerstone of treatment for MIBC, but it’s not suitable for everyone. Many patients are ineligible due to pre-existing kidney problems, hearing loss, or other health conditions. For these individuals, radical cystectomy – surgical removal of the bladder – has traditionally been the primary option. However, a growing body of evidence suggests that adding systemic therapy before surgery, known as neoadjuvant therapy, can improve survival rates. The challenge has been finding effective neoadjuvant regimens that don’t rely on cisplatin.

The phase III EV303/KEYNOTE-905 trial, published in the New England Journal of Medicine, investigated the efficacy of perioperative enfortumab vedotin (EV) plus pembrolizumab in this patient population. “Perioperative” means treatment given both before and after surgery. The trial enrolled 344 patients with stage T2–T4a N0M0 or T1–T4a N1M0 bladder cancer who were able to undergo surgery but were ineligible for or declined cisplatin-based chemotherapy. Participants were randomly assigned to receive either EV plus pembrolizumab or surgery alone.

Key Findings: Event-Free and Overall Survival

The results were compelling. At a median follow-up of 25.6 months, estimated event-free survival (EFS) – meaning the time until the cancer returns or a patient dies – was 74.7% in the EV plus pembrolizumab group, compared to 39.4% in the surgery-alone group (hazard ratio 0.40, 95% CI 0.28 to 0.57, P<0.001). As detailed in the Journal of the National Cancer Institute, this translates to a substantial reduction in the risk of disease recurrence or death.

overall survival (OS) was also significantly improved with the combination therapy, reaching 79.7% versus 63.1% in the control group (hazard ratio 0.50, 95% CI 0.33 to 0.74, P<0.001). Perhaps most striking was the high rate of pathological complete response (pCR) – the absence of any detectable cancer cells in the bladder and surrounding tissue after surgery – observed in the EV plus pembrolizumab arm (57.1%) compared to just 8.6% in the surgery-alone group (estimated difference 48.3 percentage points, 95% CI 39.5 to 56.5, P<0.001).

Understanding the Therapies

Enfortumab vedotin is an antibody-drug conjugate. In other words it combines an antibody that specifically targets a protein called nectin-4, which is often found in high levels on bladder cancer cells, with a chemotherapy drug. The antibody delivers the chemotherapy directly to the cancer cells, minimizing damage to healthy tissues. Pembrolizumab, is an immune checkpoint inhibitor. It works by blocking a protein called PD-1, which helps cancer cells evade the immune system, allowing the body’s own defenses to attack the tumor. The combination aims to both directly kill cancer cells and boost the immune response against them.

Limitations and Remaining Questions

While these findings are highly encouraging, it’s important to acknowledge the study’s limitations. The trial population consisted of patients ineligible for cisplatin, meaning the results may not be directly applicable to patients who can receive cisplatin-based chemotherapy. Further research is needed to determine whether this combination is also beneficial in the broader MIBC population.

the long-term effects of this treatment regimen are still unknown. The median follow-up period of 25.6 months, while substantial, is not long enough to fully assess the durability of the response and potential late-onset side effects. Ongoing monitoring of trial participants will be crucial to gather more data on these aspects. The trial also didn’t specifically assess quality of life, which is an important consideration for patients undergoing cancer treatment.

What This Means for Patients

The approval of this combination therapy represents a significant step forward for patients with resectable MIBC who are unable to receive cisplatin. It provides a new, effective treatment option that can improve both survival and the likelihood of achieving a complete response. However, it’s crucial for patients to discuss the potential benefits and risks of this regimen with their oncologist to determine if it’s the right choice for them.

The data from the EV303/KEYNOTE-905 trial have already supported FDA approval of this perioperative approach, signaling a change in standard of care. This approval is based on the demonstrated superiority of EV plus pembrolizumab over surgery alone in this specific patient population.

The Path Forward: Ongoing Research and Surveillance

The approval of this combination is not the end of the story. Researchers are continuing to investigate ways to further optimize treatment for MIBC. Ongoing clinical trials are exploring the apply of EV plus pembrolizumab in combination with other therapies, as well as its potential role in earlier stages of the disease.

health authorities will continue to monitor the long-term outcomes of patients treated with this regimen to identify any potential safety concerns and refine treatment guidelines accordingly. Surveillance programs will also be essential to track the emergence of any resistance to these therapies and develop strategies to overcome it. The evolving landscape of MIBC treatment underscores the importance of continued research and collaboration to improve outcomes for patients facing this challenging disease.